Analysis of Curcumin as a Radiosensitizer in Cancer Therapy with Serum Survivin Examination: Randomised Control Trial

Document Type : Research Articles


1 Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjajaran, Bandung, Indonesia.

2 Department of Obstetrics and Gynecology, School of Medicine, Universitas Sam Ratulangi, Manado, Indonesia.


Objective: One of the important treatments for cervical cancer is radiation therapy. This study sought to determine the role of curcumin as a radio-sensitizing agent for use with radiation therapy for cervical cancer. To accomplish this, we assessed the levels of survivin, which is an anti-apoptotic protein that plays a role in cell division and apoptosis inhibition. Method: This study used a quasi-experimental design, including a pretest–posttest control group design approach. The study subjects included cervical carcinoma stage IIB–IIIB patients who were scheduled to undergo surgery at the Hasan Sadikin Hospital Bandung during the research period. The advanced cervical cancer patients were assigned to two groups: i) those who received curcumin + radiation therapy and ii) those who received placebo + radiation therapy. Results: In the group treated with curcumin + radiation, 15 (75%) patients showed decreased survivin levels and 5 (25%) showed increased survivin levels. Whereas, in the placebo + radiation group, there were 8 (40%) patients who showed decreased survivin levels and 12 (60%) who showed increased survivin levels. Conclusion: In conclusion, curcumin is an effective, alternative radiosensitizer agent for application in cervical cancer treatment.


Main Subjects

Volume 22, Issue 1
January 2021
Pages 139-143
  • Receive Date: 15 September 2020
  • Revise Date: 21 December 2020
  • Accept Date: 15 January 2021
  • First Publish Date: 15 January 2021